Roche Expects Sales, Earnings Growth

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results
The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the CEO said it remained committed to keeping its R&D spending broadly flat in 2025.
Roche sees high single-digit core profit growth in 2025
Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year, helped by lower costs and growth from drugs such as eye treatment Vabysmo and cancer drug Phesgo.
Roche Sees Profit Growth Outpacing Sales With Deals Ahead
Roche Holding AG said profit will probably outpace sales growth this year as the Swiss drugmaker works to keep research costs in check and looks for deals to build its pipeline of experimental medicines.
Roche FY24 Core Operating Profit Rises; Sales Up 7% At CER
Roche (RHHBY) reported that its fiscal 2024 IFRS net income decreased by 19%, or 26% in Swiss francs, to 9.2 billion francs, mainly
We had a strong 2024 and expect momentum to carry into 2025, says Roche CEO
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings. Boat packed with migrants intercepted amid Trump's mass deportation effort I couldn't get hired for a year—it changed my attitude toward work: 'Perspective comes at an extremely high cost' What we know about the plane and military helicopter crash in D.
Roche Bobois Slightly Misses 2024 Revenue Guidance, Says China Boosted Q4
The upscale French furniture-maker posted preliminary revenues of 414 million euros for the full year, but said its fourth ...
Wafaa Mamilli To Join Roche As Chief Digital Technology Officer
Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles she has held at Zoetis and at Eli Lilly.
BioSpace6h
Roche to Stay ‘Disciplined’ With Deals in 2025
Roche will continue a careful approach to high-priced deals, putting science at the center of its business development decisions, executives said Thursday.
FiercePharma6h
Vabysmo crosses $4B mark, Polivy joins blockbuster club as Roche preps for key readouts
After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. | After repeatedly wowing investors, Roche’s star eye med ...
FierceBiotech12h
Roche drops HER2 bispecific, Xencor-partnered cytokine from early-phase pipeline
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. | Roche has given two early-phase bispecifics the heave-ho ...
Roche Expected to Report Higher Earnings, Sales -- Earnings Preview
EARNINGS FORECAST: Roche's core earnings per share are expected to come in at 18.59 francs, according to the Visible Alpha consensus. For 2023, the company reported core EPS of 18.57 francs. As of ...
FiercePharma2d
Roche's breast cancer entrant Itovebi bolsters clinical profile with overall survival win
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
Bernstein Sticks to Their Buy Rating for Roche Holding AG (RHHVF)
Bernstein analyst Justin Smith maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF340.00.
Pharm Exec1h
Roundup: Top Pharma Companies Report Q4 Earnings, Highlighting Revenue Trends and Market Shifts
Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...